| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 618.9 | 699.9 |
| Profit before tax | -62.9 | -756.9 |
| Net income | -53.8 | -733.0 |
| EPS (diluted, $ a share) | $-0.78 | $-10.78 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -11.6% |
|---|---|
| Operating margin | -1.2% |
10-Q filed with the SEC, NASDAQ: QDEL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
QuidelOrtho Corp: key numbers
- Share price
- $10.21Close, Nov 16
- Market cap
- $701M
- Shares outstanding
- 68.61MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from QuidelOrtho Corp
All →QuidelOrtho Earnings Call: Key Takeaways
QuidelOrtho is undergoing a major restructuring to offset severe China headwinds and high leverage, shifting to a business-unit model while narrowing revenue guidance downward.
- Call
- Nov 3, 2026, 5:00 PM ET
QuidelOrtho Financial Results
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.
- Term
- Q3 2026
“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”
Brian J. Blaser, President and Chief Executive Officer
QuidelOrtho $3.4B Debt Financing with Bank of America, N.A.
QuidelOrtho Corporation entered into an amendment to its existing credit agreement to reset financial covenant levels through September 30, 2029, providing a 'Covenant Relief Period' with adjusted leverage and interest coverage ratios. The underlying $3.4 billion financing package includes a $1.15 billion Term Loan A, a $100 million delayed draw facility, a $1.45 billion Term Loan B, and a $700 million revolving credit facility.
- Value
- $3.4B
- Counterparty
- Bank of America, N.A.
- Term
- through Sep 2029